Neurocrine and Voyager Collaborated to Develop Multiple Gene Therapies for the Treatment of Neurological Diseases
- Voyager to receive $175M up front incl. ~$136M in cash & ~$39M in equity investment at $8.88/share representing a 50% premium to the avg. price of Voyager’s stock. Neurocrine will lead development & commercialization expenses for all programs
- Voyager is also eligible to receive development & commercial milestones (i) ~$985.0M (If it declines its option for cost and profit sharing) & ~$950.0M for the GBA1 program (ii) ~$175.0M & ~$275.0M each for 3 new gene therapy programs along with royalties on US and Ex-US net sales
- Neurocrine to get the global rights to Voyager’s GBA1 program, 3 gene therapy programs directed to rare CNS targets using Voyager’s TRACER capsids along with additional equity in Voyager. Voyager gets the rights to co-develop & co-commercialize the GBA1 program with Neurocrine under a 50/50 cost and profit-sharing in the US, based on the P-I trial results
Ref: Globenewswire | Image: Neurocrine
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.